This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Skip to main content
United Kingdom | EN-GB

Add a bookmark to get started

Cortex - Life Sciences Insights

| less than a minute read

Sanofi Enters the Race to Develop a New Drug for Multiple Sclerosis

Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the blood-brain barrier making it an attractive candidate not only for MS but for the treatment of other neurological disease.

Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.


life science, ipt, usa, multiple sclerosis, neurological, blood-brain